All In Biotech

Drug Trial Radar · NCT03833180

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)

Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Mar 14, 2019

Primary completion

Dec 18, 2023

Study completion Dec 18, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).

Conditions

  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Richter Transformation Lymphoma
  • Burkitt Lymphoma
  • Lymphoplasmacytoid Lymphoma
  • T-cell Non-Hodgkin Lymphoma
  • Acute Lymphoid Leukemia
  • Acute Myeloid Leukemia
  • Waldenstrom Macroglobulinemia

Interventions

  • Zilovertamab vedotinDrug

    Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of zilovertamab vedotinTime frame: Cycle 1 (Up to 21 Days)
  2. Recommended Dosing Regimen (RDR)Time frame: Cycle 1 (Up to 21 Days)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope ( Site 0010)

    Duarte, California

  • University of California - San Diego ( Site 0003)

    La Jolla, California

  • UCLA Hematology & Oncology ( Site 0007)

    Los Angeles, California

  • University of Nebraska Medical Center ( Site 0006)

    Omaha, Nebraska

  • Northwell Health ( Site 0009)

    New Hyde Park, New York

  • Weill Cornell Medical College ( Site 0005)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0014)

    New York, New York

  • University of Rochester ( Site 0008)

    Rochester, New York

  • Memorial Sloan-Kettering Cancer Center ( Site 0019)

    Uniondale, New York

  • Oregon Health & Science University ( Site 0004)

    Portland, Oregon

  • MD Anderson Cancer Center ( Site 0001)

    Houston, Texas

  • MD Anderson Cancer Center ( Site 0011)

    Houston, Texas

  • University of Virginia Cancer Center ( Site 0012)

    Charlottesville, Virginia

  • Swedish Medical Center ( Site 0002)

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.